The clinical significance of microembolic signals in @entity1 with XXXX .

@entity1 @entity7303 @entity64 @entity2806 @entity146 @entity63 @entity73 @entity16 @entity1252 @entity1701 @entity65
BACKGROUND: @entity7303 ( @entity7303 ) have been found in about 10% of @entity1 with @entity1252 ( @entity1252 ), and have been associated with @entity146 manifestations (NPSLE), including @entity16 . OBJECTIVE: To determine the frequency of @entity7303 in @entity1 with @entity1252 , previous and further risk of @entity146 manifestations. METHODS: One hundred and nine consecutive @entity1 with previous diagnosis of @entity1252 and without acute neurological manifestations were evaluated clinically and by transcranial Doppler monitoring (1 hour) from November 2002 to March 2003. The baseline characteristics and outcomes were compared between @entity1 with and without @entity7303 . @entity1 were followed during a mean time of 4.5 years, to detect the appearance of NPSLE, including @entity64 and transient @entity63 attacks. RESULTS: @entity7303 were detected in 16 @entity1 (14.7%; range: 3-64/h); at baseline, previous @entity146 manifestations were more frequent in @entity1 with @entity7303 : 12/16 (75%) versus 46/92 (50%) (p=0.064), especially for @entity73 (p=0.036). @entity1701 and @entity65 factors did not differ between groups at baseline and follow-up, neither the proportion of patients on antiplatelet agents. At follow-up, two @entity1 from the @entity7303 positive group and six from the @entity7303 negative group developed a new @entity146 manifestation (p=not significant). CONCLUSION: This study supports an association of @entity7303 and a history of NPSLE, especially @entity73 . @entity7303 were not associated with an increased risk of @entity2806 and other neurological manifestations at follow-up.
